Regentis Biomaterials Ltd. has announced a significant step in its commercialization strategy by signing an exclusive distribution agreement with AMI Technologies. This partnership will allow AMI to distribute Regentis's GelrinC product, a proprietary implant designed for knee cartilage repair, in Israel. The agreement is expected to bolster Regentis's market presence and revenue potential in the orthopedic sector.

Founded in 1986, AMI Technologies is a leading Israeli distributor of advanced medical technologies, with a strong focus on orthopedic products. The company has established relationships with key orthopedic surgeons and medical institutions in Israel, making it well-positioned to support the commercial launch of GelrinC.

The agreement includes minimum purchase commitments from AMI, with Regentis anticipating initial revenue contributions beginning in 2027. GelrinC is already approved in Israel and Europe for knee cartilage repair, and it is currently undergoing a pivotal Phase III trial in the United States.

Regentis's CEO, Ehud Geller, expressed optimism about the partnership, stating, "Israel represents an attractive initial commercial market for GelrinC, and this agreement marks an important step in expanding our commercialization activities in parallel with what we are doing in Europe." He emphasized AMI's extensive presence in the Israeli orthopedic market and its strong track record in introducing advanced medical technologies.

Rami Dulberg, President of AMI Technologies, also highlighted the importance of GelrinC, stating, "Cartilage injuries present a significant treatment challenge, and we believe GelrinC offers an important new option for patients and orthopedic surgeons in Israel." AMI will collaborate with Regentis to establish reimbursement coverage for GelrinC with leading Health Maintenance Organizations (HMOs) in Israel, which is crucial for patient access.

Regentis Biomaterials Ltd. is focused on developing innovative tissue repair solutions, particularly in the orthopedic field. Its GelrinC product is a cell-free, off-the-shelf hydrogel implant that aims to provide a reliable and cost-effective treatment for knee cartilage defects. The company is dedicated to restoring health and enhancing the quality of life for patients with orthopedic needs.

As the orthopedic market continues to evolve, this partnership between Regentis and AMI Technologies may impact competitors and reshape the landscape of cartilage repair solutions in Israel.

Details were not available in the SEC filing regarding further developments or future actions following this agreement.